Wednesday, February 04, 2026 9:37:59 PM
Seamless ESGCT 2024 (found in a PDF on their site): Highlights
P0670 - Reprogramming Large Serine Recombinases (LSRs) for Site-Specific Integration
Key Points:
Seamless uses a proprietary search motif to identify target sites in almost all coding genes and human safe harbour sites, giving broad applicability beyond sequences similar to natural recombinase targets.
Through directed evolution and rational design, they engineered LSRs to target four selected sites in the human genome.
Engineered LSR clones showed high activity in bacteria, which translated well to human cells.
A leading engineered enzyme, IntSTX-SH2, could precisely integrate DNA into the SH2 locus in human cells.
Optimisation to IntSTX-SH2 2.0 produced a three-fold activity improvement over the first generation, with room for further enhancement.
P0590 - Zinc-Finger Dependent Recombinases (ZFD-Conditional Editing)
Key Points:
Seamless combined Zinc-Finger Binding Domains (ZFDs) with tyrosine recombinases (Y-SSRs) and LSRs.
Engineered variants were inactive without the correct ZFD target site and reactivated only when the site was present, ensuring high specificity.
This strategy increases efficiency and precision of recombinases.
Expands the suite of DNA editing techniques, giving the ability to program edits in a conditional, highly controlled manner.
So Seamless is moving beyond traditional recombinase limits by searching almost all genes for editable sites, programming LSRs to target chosen human sequences, enhancing efficiency via iterations (like IntSTX-SH2 2.0), and increasing specificity with zinc-finger conditional activation.
This positions Seamless with a platform capable of safe, precise, and flexible gene integration, competitive with Sangamo’s MINT, but with greater programmability for new target sites and conditional editing capability (via ZFDs).
All this builds directly on the foundational work described in these papers https://www.nature.com/articles/s41587-023-02121-y https://link.springer.com/article/10.1186/s13059-023-03097-3 https://academic.oup.com/nar/article/51/10/5285/7157522
P0670 - Reprogramming Large Serine Recombinases (LSRs) for Site-Specific Integration
Key Points:
Seamless uses a proprietary search motif to identify target sites in almost all coding genes and human safe harbour sites, giving broad applicability beyond sequences similar to natural recombinase targets.
Through directed evolution and rational design, they engineered LSRs to target four selected sites in the human genome.
Engineered LSR clones showed high activity in bacteria, which translated well to human cells.
A leading engineered enzyme, IntSTX-SH2, could precisely integrate DNA into the SH2 locus in human cells.
Optimisation to IntSTX-SH2 2.0 produced a three-fold activity improvement over the first generation, with room for further enhancement.
P0590 - Zinc-Finger Dependent Recombinases (ZFD-Conditional Editing)
Key Points:
Seamless combined Zinc-Finger Binding Domains (ZFDs) with tyrosine recombinases (Y-SSRs) and LSRs.
Engineered variants were inactive without the correct ZFD target site and reactivated only when the site was present, ensuring high specificity.
This strategy increases efficiency and precision of recombinases.
Expands the suite of DNA editing techniques, giving the ability to program edits in a conditional, highly controlled manner.
So Seamless is moving beyond traditional recombinase limits by searching almost all genes for editable sites, programming LSRs to target chosen human sequences, enhancing efficiency via iterations (like IntSTX-SH2 2.0), and increasing specificity with zinc-finger conditional activation.
This positions Seamless with a platform capable of safe, precise, and flexible gene integration, competitive with Sangamo’s MINT, but with greater programmability for new target sites and conditional editing capability (via ZFDs).
All this builds directly on the foundational work described in these papers https://www.nature.com/articles/s41587-023-02121-y https://link.springer.com/article/10.1186/s13059-023-03097-3 https://academic.oup.com/nar/article/51/10/5285/7157522
Recent SGMO News
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/22/2026 08:01:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/06/2026 11:08:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:15:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/30/2026 09:29:20 PM
- Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results • GlobeNewswire Inc. • 03/30/2026 08:01:00 PM
- Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call • GlobeNewswire Inc. • 03/19/2026 08:03:00 PM
- Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease • GlobeNewswire Inc. • 03/09/2026 12:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2026 02:40:15 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/04/2026 01:35:30 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/04/2026 01:31:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 09:07:22 PM
- Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026 • GlobeNewswire Inc. • 02/03/2026 09:05:00 PM
- Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering • GlobeNewswire Inc. • 02/03/2026 02:10:43 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/03/2026 02:07:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/03/2026 01:55:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 09:14:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/26/2026 09:13:32 PM
